Live Breaking News & Updates on Phase 3 Laura Trial Nct03521154

Stay updated with breaking news from Phase 3 laura trial nct03521154 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Maintenance Osimertinib Demonstrates PFS Benefit in Stage III EGFR-Mutant NSCLC

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer. ....

United States , Suresh Ramalingam , Susan Galbraith , Winship Cancer Institute Of Emory University , World Health Organization , Oncology Research Development At Astrazeneca , Winship Cancer Institute , Emory University , South America , Oncology Research , Egfr Mutant Nsclc , Phase 3 Laura Trial Nct03521154 ,